Myeloma | Tumor

Myeloma Therapies Create an ‘Optimistic Picture’ for Patients’ Futures

April 6th 2021, 9:00pm

Video

In an interview, Dr. Andrew Yee of Massachusetts General Hospital discusses how a multiple myeloma diagnosis affects a patient’s life and how hopeful he is about helping them lead normal lives.

What It’s Like to Be a Myeloma Millennial, Or, ‘Myelennial’

April 5th 2021, 9:00pm

Video

In an interview, Dr. Nina Shah of UCSF Helen Diller Family Comprehensive Cancer Center explains what a myeloma millennial, or ‘myelennial,’ is, and how recent advances in multiple myeloma treatments inspired the term.

Treatments for Multiple Myeloma Are Transforming Lives

April 1st 2021, 9:00pm

Article

The biggest fear for many patients, according to an expert from The University of Texas MD Anderson Cancer Center, is when they hear that myeloma, for most patients, is not curable. However, she notes that every few years patient survival is increasing.

FDA Approves Addition of Sarclisa to Standard of Care for Relapsed/Refractory Myeloma

March 31st 2021, 10:19pm

Article

“This approval is an important advancement for patients whose disease has relapsed and reinforces the potential for Sarclisa to become a standard of care in relapsed or refractory multiple myeloma,” said Dr. Thomas G. Martin.

‘Knowledge Is Power’ When Learning About Treatments for Late Relapsed/Refractory Multiple Myeloma

March 31st 2021, 1:00pm

Article

An expert discusses therapies that are changing the treatment landscape and the research to make this disease more livable.

Many Factors Influence Which Cell-Based Treatment Options are Best for Patients with Multiple Myeloma, Expert Says

March 30th 2021, 9:00pm

Article

Efficacy is one of the most important drivers in determining which cell-based therapy a patient with multiple myeloma receives, according to an expert. However, she says, other factors, such as how aggressive the disease is, may play a major role.

FDA Approves First CAR-T Cell Therapy for Multiple Myeloma

March 28th 2021, 3:15pm

Article

Abecma is the first cell-based gene therapy approved for the treatment of patients with relapsed and refractory multiple myeloma who did not respond to at least four treatments, or whose disease returned after those four lines of therapy.

Spotlighting New and Emerging Therapies in Myeloma

March 24th 2021, 9:00pm

Article

There is a lot of hype on T-cell engagers and CAR T-cell therapy, but there are other new and exciting immunotherapies in myeloma not talked about that may be approved in the near future, according to an expert.

Multiple Myeloma 101: An Incurable But ‘Very Treatable’ Disease

March 22nd 2021, 3:00pm

Article

Although a multiple myeloma diagnosis can be overwhelming for patients, an expert from the Massachusetts General Hospital Cancer Center notes how the disease is very treatable, and that patients can go on to lead full lives.

The Basics of Multiple Myeloma

March 18th 2021, 3:00pm

Podcast

In this episode of the “CURE® Talks Cancer” podcast, we’re honoring Multiple Myeloma Awareness Month by speaking with Dr. Andrew Yee, about the signs and symptoms of this rare form of cancer, what the current treatment paradigm looks like and what advice he has for newly diagnosed patients.